Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent progress his Department has made on implementing the Dame Barbara Windsor Dementia Goals programme.

The Dame Barbara Windsor Dementia Goals programme, with up to £150 million expected to be allocated to, or aligned with it, aims to speed up the development of new treatments for dementia and neurodegenerative conditions by accelerating innovations in biomarkers, clinical trials, and implementation. This is co-chaired by Hilary Evans-Newton CBE and Professor Nadeem Sarwar.

So far, the programme has invested approximately £100 million into biomarker innovation projects, experimental medicine studies, and clinical trial infrastructure. This covers a broad range of biomarker technologies and studies to help researchers, patients, and industry partners work together to better understand how dementia begins and progresses. This amount also supports the Medical Research Council’s Dementia Trials Accelerator which aims to embed more innovation in how clinical trials are designed and delivered in order to increase the speed and quality, while driving down the cost of large-scale trials, as well as the National Institute for Health and Care Research’s UK Dementia Trials Network which seeks to speed up early-stage clinical trials.

The programme is now setting up the Neurodegeneration Initiative, which will be a globally unique, not-for-profit, industry led, public-private partnership with charitable status, that will work together across the Government, industry, academia, the National Health Service, and third sector, and will deliver the programme’s remaining objectives.